Study Summary
This trial tests a combo of drugs to better treat advanced solid tumors. It blocks energy production tumor cells need & may kill them.
- Stage IV Pancreatic Cancer
- Metastatic Biliary Tract Carcinoma
- Biliary Tract Carcinoma
- Refractory Urothelial Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Refractory Lung Adenocarcinoma
- Cancer
- Pancreatic Cancer
- Stage III Pancreatic Cancer
- Cholangiocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Bladder Cancer
- Pancreatic Cancer (Refractory)
- Colorectal Cancer
- Metastatic Pancreatic Endocrine Carcinoma
- Stage II Pancreatic Cancer
- Ovarian Cancer
- Metastatic Urothelial Carcinoma of the Ureter
- Stage IV Ovarian Cancer
- Stage III Ovarian Cancer
- Stage III Colorectal Cancer
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma
- Refractory Gastroesophageal Junction Adenocarcinoma
- Stage IV Colorectal Cancer
- Stage IV Lung Cancer
- Lung Cancer
- Refractory Colorectal Cancer
- Stage III Lung Cancer
- Refractory Ovarian Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Time from baseline to disease progression, initiates subsequent anti-cancer therapy, or 24 months (whichever occurs first)
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
3 Treatment Groups
COHORT 2 (Devimistat, 5-FU, HCQ)
1 of 3
COHORT 3 (Devimistat, 5-FU, HCQ, Gemcitabine)
1 of 3
COHORT 1 (Devimistat, 5-FU, HCQ)
1 of 3
Experimental Treatment
94 Total Participants · 3 Treatment Groups
Primary Treatment: COHORT 2 (Devimistat, 5-FU, HCQ) · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What deleterious effects may arise from the utilization of Devimistat, 5-FU, and HCQ (COHORT 1)?
"Due to the fact it is a Phase 2 trial, with some preliminary safety data but none in regards to efficacy, our team at Power have rated the security of COHORT 1 (Devimistat, 5-FU, HCQ) as an intermediate level 2." - Anonymous Online Contributor
Are participants being actively enrolled in this investigation?
"According to information from clinicaltrials.gov, this trial is no longer enrolling patients as of February 6th 2023. Since then, it has been superseded by over six thousand other studies that are actively seeking participants." - Anonymous Online Contributor